Vigil Neuroscience Stock Today
| VIGL Stock | USD 2.19 0.02 0.90% |
Performance0 of 100
| Odds Of DistressLess than 50
|
Vigil Neuroscience is selling for 2.19 as of the 30th of January 2025. This is a 0.9 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.1. Vigil Neuroscience has 50 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 2nd of October 2024 and ending today, the 30th of January 2025. Click here to learn more.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc. The company has 40.88 M outstanding shares of which 736.51 K shares are at this time shorted by private and institutional investors with about 5.31 trading days to cover. More on Vigil Neuroscience
Moving together with Vigil Stock
Moving against Vigil Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Vigil Stock Highlights
| CEO President | Ivana JD |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Vigil Neuroscience (VIGL) is traded on NASDAQ Exchange in USA. It is located in 100 Forge Road, Watertown, MA, United States, 02472 and employs 64 people. Vigil Neuroscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 90.34 M. Vigil Neuroscience conducts business under Biotechnology sector and is part of Health Care industry. The entity has 40.88 M outstanding shares of which 736.51 K shares are at this time shorted by private and institutional investors with about 5.31 trading days to cover.
Vigil Neuroscience currently holds about 148.91 M in cash with (70.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vigil Neuroscience Probability Of Bankruptcy
Ownership AllocationVigil Neuroscience shows a total of 40.88 Million outstanding shares. The majority of Vigil Neuroscience outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vigil Neuroscience to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vigil Neuroscience. Please pay attention to any change in the institutional holdings of Vigil Neuroscience as this could imply that something significant has changed or is about to change at the company. Also note that roughly five hundred eighty thousand four hundred eighty-nine invesors are currently shorting Vigil Neuroscience expressing very little confidence in its future performance.
Check Vigil Ownership Details
Vigil Neuroscience Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Vigil Neuroscience market risk premium is the additional return an investor will receive from holding Vigil Neuroscience long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | (0.37) |
Vigil Stock Against Markets
Vigil Neuroscience Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Spyridon MD | Chief Officer | Profile | |
| Weeteck Yeo | Senior Operations | Profile | |
| Jessica PMP | Senior Management | Profile | |
| Mr DABT | Senior Development | Profile | |
| Christopher JD | General Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.